Tag: business
-
Why AstraZeneca Investors Rejected a $400 Billion BMS Megadeal
Reports of a potential $400 billion AstraZeneca–Bristol Myers Squibb combination triggered a sharp market backlash and renewed questions about the value of Big Pharma megamergers.
-
Curium to Acquire Lantheus in an $8 Billion Radiopharma Deal
Curium’s acquisition of Lantheus could create a global radiopharma leader by combining isotope manufacturing, diagnostics, and commercial scale.
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-
AstraZeneca Keeps Its $80 Billion Goal Despite a Major Trial Setback
AstraZeneca reaffirmed its $80 billion revenue ambition after reporting solid second-quarter results. Strong oncology and rare disease sales helped restore confidence following the failure of a major Wainua trial.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-
Pfizer Lands Metsera Acquisition After Novo Nordisk Bows Out of $10 B Bidding War
Pfizer’s acquisition of Metsera secures a high-potential obesity-drug pipeline — but because Metsera’s assets are early-stage, the deal carries meaningful regulatory and execution risk.
-
Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs
As the battle for dominance in obesity treatment intensifies, Eli Lilly and Novo Nordisk are racing ahead with groundbreaking drugs. But with politics and market power in play, the story goes far beyond science — it’s shaping the future of healthcare itself.
-
Bidding War Heats Up: Pfizer vs. Novo Nordisk in the Race to Acquire Metsera
The intense bidding war between Pfizer and Novo Nordisk over Metsera underscores just how fiercely the global obesity-drug market is being contested.
-
Eli Lilly’s Major Netherlands Plant Investment: Scaling Supply for Oral Obesity Therapy
On November 4, 2025, Eli Lilly and Company announced a multi-billion-dollar investment in a new manufacturing facility in the Netherlands to support global rollout of its oral obesity drug orforglipron and fortify its trans-Atlantic production network.
-
The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.